APA

Kleerekooper I., van Kempen Z. L. E., Leurs C. E., Dekker I., Rispens T., Lissenberg-Witte B. I., van Munster C. E. P., de Jong B. A., van Oosten B. W., Uitdehaag B. M. J., Wattjes M. P. & Killestein J. (2018). Disease activity following pregnancy-related discontinuation of natalizumab in MS. : Neurology(R) neuroimmunology & neuroinflammation.

Chicago

Kleerekooper Iris, van Kempen Zoé L E, Leurs Cyra E, Dekker Iris, Rispens Theo, Lissenberg-Witte Birgit I, van Munster Caspar E P, de Jong Brigit A, van Oosten Bob W, Uitdehaag Bernard M J, Wattjes Mike P and Killestein Joep. 2018. Disease activity following pregnancy-related discontinuation of natalizumab in MS. : Neurology(R) neuroimmunology & neuroinflammation.

Harvard

Kleerekooper I., van Kempen Z. L. E., Leurs C. E., Dekker I., Rispens T., Lissenberg-Witte B. I., van Munster C. E. P., de Jong B. A., van Oosten B. W., Uitdehaag B. M. J., Wattjes M. P. and Killestein J. (2018). Disease activity following pregnancy-related discontinuation of natalizumab in MS. : Neurology(R) neuroimmunology & neuroinflammation.

MLA

Kleerekooper Iris, van Kempen Zoé L E, Leurs Cyra E, Dekker Iris, Rispens Theo, Lissenberg-Witte Birgit I, van Munster Caspar E P, de Jong Brigit A, van Oosten Bob W, Uitdehaag Bernard M J, Wattjes Mike P and Killestein Joep. Disease activity following pregnancy-related discontinuation of natalizumab in MS. : Neurology(R) neuroimmunology & neuroinflammation. 2018.